Australia has closed a deal for 300,000 courses of an antiviral pill showing promising signs of slashing COVID-19 deaths and hospitalisations.
Molnupiravir is still being trialled in the US and is yet to gain regulatory authorisation.
A lab technician holds the COVID-19 treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt, on June 25, 2020. Amr Abdallah Dalsh/Reuters
|Updated:
